Literature DB >> 197185

Secretion of the arginine-rich and A-I apolipoproteins by the isolated perfused rat liver.

T E Felker, M Fainaru, R L Hamilton, R J Havel.   

Abstract

Rates of secretion of the arginine-rich and A-I apolipoproteins into perfusates of rat livers were measured by specific radioimmunoassays. Livers were perfused for 6 hr in a recirculating system in the presence or absence of 5,5'-dithionitrobenzoic acid, an inhibitor of lecithin-cholesterol acyltransferase. Arginine-rich apoprotein (ARP) was secreted at a constant or increasing hourly rate of about 40 micro g/g liver, whereas the rate of accumulation of apoprotein A-I decreased progressively from about 12 to less than 5 micro g/g liver. These rates were not affected by inhibition of lecithin-cholesterol acyltransferase. The distribution of these two apolipoproteins was also measured in ultracentrifugally separated lipoprotein fractions from perfusates and blood plasma. Apoprotein A-I was mainly in high density lipoproteins, with the remainder in proteins of density > 1.21 g/ml. The percent of apoprotein A-I in the latter fraction was lowest in plasma (5%); in perfusates it was greater when the enzyme inhibitor was present (33%) than in its absence (11%). By contrast much less ARP was in proteins of d > 1.21 g/ml in perfusates than in blood plasma. Discoidal high density lipoproteins, recovered from perfusates in which lecithin-cholesterol acyltransferase was inhibited, contained much more arginine-rich apoprotein than apoprotein A-I (ratio = 10:1). The ratio in spherical plasma HDL was 1:7 and that in perfusate high density lipoproteins obtained in the absence of enzyme inhibitor was intermediate (2:1). It is concluded that: 1) the arginine-rich apoprotein is a major apolipoprotein whereas apoprotein A-I is a minor apolipoprotein secreted by the perfused rat liver; 2) the properties of the high density lipoproteins produced in this system are remarkably similar to those found in humans with genetically determined deficiency of lecithin-cholesterol acyltransferase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 197185

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  18 in total

1.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

2.  Intestinal apoproteins during fat absorption.

Authors:  G Schonfeld; E Bell; D H Alpers
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

Review 3.  Apolipoprotein E.

Authors:  V I Zannis; J L Breslow
Journal:  Mol Cell Biochem       Date:  1982-01-16       Impact factor: 3.396

4.  Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile.

Authors:  P G Elmberger; A Kalén; U T Brunk; G Dallner
Journal:  Lipids       Date:  1989-11       Impact factor: 1.880

5.  Biliary and fecal steroid excretion in rats fed partially hydrogenated soybean oil.

Authors:  M Sugano; T Ide; M Kohno; M Watanabe; Y J Cho; Y Nagata
Journal:  Lipids       Date:  1983-03       Impact factor: 1.880

6.  Regulation of hepatic triglyceride synthesis in diabetic rats.

Authors:  V K Murthy; J C Shipp
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

7.  Lipoprotein secretion by isolated perfused livers from streptozotocin-diabetic rats.

Authors:  E M Berry; E Ziv; H Bar-On
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

8.  Mechanism of action of gemfibrozil on lipoprotein metabolism.

Authors:  K Saku; P S Gartside; B A Hynd; M L Kashyap
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Secretion of lipoprotein-X by perfused livers of rats with cholestasis.

Authors:  T E Felker; R L Hamilton; R J Havel
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  Characterization of monoclonal antibodies against human apolipoprotein E.

Authors:  R W Milne; P Douste-Blazy; Y L Marcel; L Retegui
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.